An Open-Label, Dose Escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel When Applied on Day 1 and Day 2 to Actinic Keratoses on the Shoulders, Chest, Back or Arms Followed by a Post-Treatment Follow-up Period Lasting at Four Weeks

Inclusion Criteria:

- Male or Female at least 18 years of age

- One AK lesion selected for treatment on the shoulders, chest, back or arms

- Longest diameter of the selected lesion between 3mm and 15mm

- Screening laboratory values within the references ranges as defined by the laboratory
or "out of range" test results that are clinically acceptable to the Investigator

- Ability to follow study instructions and likely to complete all study requirements

- Written informed consent has been obtained

- Written Authorization for the Use and Release of Health and Research Study
Information has been obtained

- Agreement from the patient to allow photographs of the selected lesion to be taken
and used as part of the study data package.

Exclusion Criteria:

- Females of child bearing potential (a female is considered to be of childbearing
potential unless she is post-menopausal, i.e no menses for at least 12 consecutive
months or is without a uterus)

- Actinic Keratoses selected for treatment that are hypertrophic

- Location of the selected actinic keratoses lesion:

1. within 5 cm of a scar

2. within 5 cm of any actinic keratosis lesion not selected for treatment

3. within 5 cm of an incompletely healed wound

4. on the breast

5. within 5 cm of an area previously treated with surgical excision

- Presence of suspected basal cell carcinoma or squamous cell carcinoma within 5 cm of
the selected treatment area

- Presence of known or suspected metastatic disease

- History or evidence of skin conditions other than AK which would interfere with the
evaluation of the study medication (e.g eczema, unstable psoriasis, xeroderma
pigmentosa)

- Known sensitivity to any of the ingredients in the study medication

- A cosmetic or therapeutic procedure (e.g liquid nitrogen, curettage, dermabrasion,
medium or greater depth chemical peel, laser resurfacing) located within 10cm of the
actinic keratosis lesion selected for treatment during three months prior to study
entry or anticipated treatment within 10cm of the selected lesion during the study

- Within four weeks prior to study entry, a cosmetic or therapeutic procedure located
anywhere on the body

- Within three months prior to the study entry, treatment with 5-flourouracil,
imiquimod, diclofenac, masoprocol, or photodynamic therapy for lesions located within
10cm of the actinic keratosis lesion selected for treatment

- Within four weeks prior to study entry, treatment with 5-flourouracil, imiquimod,
masoprocol, or photodynamic therapy for lesion located anywhere on the body

- Previous treatment with other immunomodulators (e.g vinblastine, podophyllin,
colhamin, camptothecin), cytotoxic drugs (e;g cyclophosphamide, azathioprine,
chlorambucil, nitrogen mustard, methotrexate), or interferon/interferon inducers
(other than imiquimod)within four weeks prior to study entry

- Previous treatment with psoralen plus UVA or use of UVB therapy within six months
prior to study entry

- Patients who require or desire excess or prolonged exposure to ultraviolet light(e.g
sunlight, tanning beds) during the study

- Use of medications that suppress the immune system within four weeks prior study
entry (e.g cyclosporine, prednisone, methotrexate, alefacept, infliximab)

- Within four weeks prior to study entry, use of topical retinoids or light chemical
peels located within 10cm of the actinic keratosis lesion selected for treatment

- Use of systemic retinoids (e.g isotretinoin, acitretin, bexarotene) within six months
prior to study entry

- Within four weeks prior to study entry, use of acid containing products (e.g
salicylic acids or fruit acids such as alpha and beta hydroxy acids and glycolic
acids). located within 10 cm of the actinic keratosis lesion selected for treatment

- Anticipated need to use acid containing products on the treatment area during the
study ( e.g salicylic acids or fruit acids, such as alpha and beta hydroxy acids and
glycolic acids)

- Concurrent disease that supresses the immune system(e.g HIV)

- Uncontrolled systemic disease (e.g uncontrolled hypertension)

- Anticipated need for surgery or hospitalization during the study

- Current evidence of chronic alcohol or drug abuse

- Current enrollment in an investigational drug or device study or participation in
such a study within 30 days of entry into this study

- Patient has a condition or is in a situation which in the Investigator's opinion may
put the patient at significant risk, may confound the study results, or may interfere
significantly with the patients participation in the study.